National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; The Board of Scientific Counselors (BSC), Centers for Disease Control and Prevention (CDC), National Center for Environmental Health (NCEH)/Agency for Toxic Substances and Disease Registry (ATSDR): Meeting, 17556 [E7-6585]

Download as PDF 17556 Federal Register / Vol. 72, No. 67 / Monday, April 9, 2007 / Notices both CDC and the Agency for Toxic Substances and Disease Registry. Dated: April 3, 2007. Diane Allen, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E7–6591 Filed 4–6–07; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; The Board of Scientific Counselors (BSC), Centers for Disease Control and Prevention (CDC), National Center for Environmental Health (NCEH)/Agency for Toxic Substances and Disease Registry (ATSDR): Meeting sroberts on PROD1PC70 with NOTICES In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92– 463), CDC and ATSDR announce the following meeting of the aforementioned committee: Times and Dates: 8 a.m.–4:45 p.m., May 17, 2007. 8 a.m.–12 p.m., May 18, 2007. Place: 1825 Century Boulevard, Atlanta, Georgia 30345. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people. Purpose: The Secretary, Department of Health and Human Services (HHS), and by delegation, the Director, CDC, are authorized under Section 301 (42 U.S.C. 241) and Section 311 (42 U.S.C. 243) of the Public Health Service Act, as amended, to: (1) Conduct, encourage, cooperate with, and assist other appropriate public authorities, scientific institutions, and scientists in the conduct of research, investigations, experiments, demonstrations, and studies relating to the causes, diagnosis, treatment, control, and prevention of physical and mental diseases and other impairments; (2) assist states and their political subdivisions in the prevention of infectious diseases and other preventable conditions and in the promotion of health and well being; and (3) train state and local personnel in health work. The BSC, NCEH/ATSDR provides advice and guidance to the Secretary, HHS; the Director, CDC, and Administrator, ATSDR; and the Director, NCEH/ATSDR, regarding program goals, objectives, strategies, and priorities in fulfillment of the agency’s VerDate Aug<31>2005 18:21 Apr 06, 2007 Jkt 211001 mission to protect and promote people’s health. The board provides advice and guidance that will assist NCEH/ATSDR in ensuring scientific quality, timeliness, utility, and dissemination of results. The board also provides guidance to help NCEH/ATSDR work more efficiently and effectively with its various constituents and to fulfill its mission in protecting America’s health. Matters To Be Discussed: An update on NCEH/ATSDR’s Office of the Director; an update on Science and Public Health and Reports; an update on the Health Department Subcommittee, the Community and Tribal Subcommittee, and the Program Peer Review Subcommittee (PPRS) Reports and Discussion; a presentation on CDC’s Web site redesign and the NCEH/ ATSDR Web site; an update on Climate Change Initiative; a presentation on the Office of Tribal Affairs’ Expert Panel Report; an update on issues from the Board; a discussion on the Office of Management and Budget Performance Assessment and Review Techniques goals and objectives; an update on the National Exposure Report; an update on Preparedness and Emergency Response priorities and portfolio; and a discussion on BSC—PPRS Draft Peer Review Report on ATSDR Site-Specific Activities. Agenda items are tentative and subject to change. FOR FURTHER INFORMATION CONTACT: Sandra Malcom, Committee Management Specialist, NCEH/ATSDR, 1600 Clifton Road, Mail Stop E–28, Atlanta, Georgia 30303; telephone 404/ 498–0003, fax 404/498–0622; E-mail: smalcom@cdc.gov. The deadline for notification of attendance is May 4, 2007. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both CDC and NCEH/ATSDR. Dated: April 2, 2007. Elaine L. Baker, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E7–6585 Filed 4–6–07; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 1978N–0224 (formerly Docket No. 78N–0224); DESI 11853] Trimethobenzamide Hydrochloride Suppositories; Withdrawal of Approval AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing the resolution of issues concerning trimethobenzamide hydrochloride suppositories. This notice announces the withdrawal of approval of the new drug application (NDA) for Tigan (trimethobenzamide hydrochloride) Suppositories. The notice also declares that the marketing of unapproved trimethobenzamide hydrochloride suppository products is unlawful and subject to FDA regulatory action. FDA is taking these actions because trimethobenzamide hydrochloride suppositories lack substantial evidence of effectiveness. ADDRESSES: Requests for an opinion on the applicability of this notice to a specific trimethobenzamide hydrochloride suppository product should be identified with Docket No. 1978N–0224 and reference number DESI 11853 and directed to the Office of Compliance, Division of New Drugs and Labeling Compliance (HFD–310), New Drugs and Labeling Team, Center for Drug Evaluation and Research, Food and Drug Administration, 11919 Rockville Pike, Rockville, MD 20852. DATE: Effective May 9, 2007. FOR FURTHER INFORMATION CONTACT: Brian L. Pendleton, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594– 2041. SUPPLEMENTARY INFORMATION: I. Background As part of its Drug Efficacy Study Implementation (DESI) program, in a notice published in the Federal Register on February 24, 1971 (36 FR 3435) (the 1971 notice), FDA announced the following conclusions regarding certain drug products that contain trimethobenzamide hydrochloride: (1) The products were probably effective for nausea and vomiting due to radiation therapy or travel sickness and for emesis associated with operative procedures, labyrinthitis, or Meniere’s syndrome; (2) they were lacking substantial evidence E:\FR\FM\09APN1.SGM 09APN1

Agencies

[Federal Register Volume 72, Number 67 (Monday, April 9, 2007)]
[Notices]
[Page 17556]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-6585]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


National Center for Environmental Health/Agency for Toxic 
Substances and Disease Registry; The Board of Scientific Counselors 
(BSC), Centers for Disease Control and Prevention (CDC), National 
Center for Environmental Health (NCEH)/Agency for Toxic Substances and 
Disease Registry (ATSDR): Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), CDC and ATSDR announce the following 
meeting of the aforementioned committee:

    Times and Dates: 8 a.m.-4:45 p.m., May 17, 2007. 8 a.m.-12 p.m., 
May 18, 2007.
    Place: 1825 Century Boulevard, Atlanta, Georgia 30345.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 75 people.
    Purpose: The Secretary, Department of Health and Human Services 
(HHS), and by delegation, the Director, CDC, are authorized under 
Section 301 (42 U.S.C. 241) and Section 311 (42 U.S.C. 243) of the 
Public Health Service Act, as amended, to: (1) Conduct, encourage, 
cooperate with, and assist other appropriate public authorities, 
scientific institutions, and scientists in the conduct of research, 
investigations, experiments, demonstrations, and studies relating to 
the causes, diagnosis, treatment, control, and prevention of physical 
and mental diseases and other impairments; (2) assist states and their 
political subdivisions in the prevention of infectious diseases and 
other preventable conditions and in the promotion of health and well 
being; and (3) train state and local personnel in health work. The BSC, 
NCEH/ATSDR provides advice and guidance to the Secretary, HHS; the 
Director, CDC, and Administrator, ATSDR; and the Director, NCEH/ATSDR, 
regarding program goals, objectives, strategies, and priorities in 
fulfillment of the agency's mission to protect and promote people's 
health. The board provides advice and guidance that will assist NCEH/
ATSDR in ensuring scientific quality, timeliness, utility, and 
dissemination of results. The board also provides guidance to help 
NCEH/ATSDR work more efficiently and effectively with its various 
constituents and to fulfill its mission in protecting America's health.
    Matters To Be Discussed: An update on NCEH/ATSDR's Office of the 
Director; an update on Science and Public Health and Reports; an update 
on the Health Department Subcommittee, the Community and Tribal 
Subcommittee, and the Program Peer Review Subcommittee (PPRS) Reports 
and Discussion; a presentation on CDC's Web site redesign and the NCEH/
ATSDR Web site; an update on Climate Change Initiative; a presentation 
on the Office of Tribal Affairs' Expert Panel Report; an update on 
issues from the Board; a discussion on the Office of Management and 
Budget Performance Assessment and Review Techniques goals and 
objectives; an update on the National Exposure Report; an update on 
Preparedness and Emergency Response priorities and portfolio; and a 
discussion on BSC--PPRS Draft Peer Review Report on ATSDR Site-Specific 
Activities.
    Agenda items are tentative and subject to change.

FOR FURTHER INFORMATION CONTACT: Sandra Malcom, Committee Management 
Specialist, NCEH/ATSDR, 1600 Clifton Road, Mail Stop E-28, Atlanta, 
Georgia 30303; telephone 404/498-0003, fax 404/498-0622; E-mail: 
smalcom@cdc.gov. The deadline for notification of attendance is May 4, 
2007.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities for 
both CDC and NCEH/ATSDR.

    Dated: April 2, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
 [FR Doc. E7-6585 Filed 4-6-07; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.